Role of Early On-Treatment Serum HBV RNA Declines in Predicting Hepatocellular Carcinoma Risk in Patients With Chronic Hepatitis B
Clinical Gastroenterology and Hepatology · 2025
DOI: 10.1016/j.cgh.2024.07.024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2025. Verfasst von Shi Liu und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China; State Key Laboratory of Organ Failure Research, G…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Hepatitis B, Chronic, RNA, Viral, Liver Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND AND AIMS: Hepatocellular carcinoma (HCC) risk prediction models established in patients with chronic hepatitis B receiving nucleos(t)ide analogue (NA) rarely include viral factors because of mediocre predictability of traditional viral markers. Here, we investigate the role of serum hepatitis B virus (HBV) RNA, a novel biomarker, in predicting HCC risk in NA-treated patients. METHODS: A total of 1374 NA-treated patients were enrolled from 2 prospective chronic hepatitis B cohorts. Serum HBV RNA was detected at baseline, year 1, 2 and 3 of treatment. Cox proportional-hazard model was used to investigate the association of HBV RNA kinetics with HCC risk. RESULTS: After a median follow-up of 5.4 years, 76 patients developed HCC. HBV RNA declines at year 1 (adjusted hazard ratio, 0.70; P = .009) and 2 (adjusted hazard ratio, 0.71; P = .016) were independently associated with HCC risk. Patients with less HBV RNA decline at year 1 (≤0.4 log10 copies/mL) or 2 (≤0.6 log10 copies/mL) had 2.22- and 2.09-folds higher HCC risk, respectively, than those with more declines. When incorporating these early on-treatment HBV RNA declines into existing HCC risk scores, including PAGE-B (age, sex, and platelets), modified PAGE-B (mPAGE-B) (age, sex, platelets, and albumin), and aMAP (age, sex, platelets, and albumin-bilirubin score) score, they could enhance their predictive performance (ie, C-index 0.814 vs 0.78 [model (PAGE-B + year-1 HBV RNA decline) vs PAGE-B score based on baseline parameters]). CONCLUSIONS: Serum HBV RNA declines at year 1 and 2 were significantly associated with on-treatment HCC risk. Incorporating early on-treatment HBV RNA declines into HCC risk prediction models can be useful tools to guide appropriate surveillance strategies in NA-treated patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China; State Key Laboratory of Organ Failure Research, Guangzhou, China; Key Laboratory of Infectious Diseases Research in Sou…
- Medical Data Analytics Centre, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China; State Key Laboratory of Digestive Disease, Institute of Digestive Disease, The Chinese U…
- Hepatology Unit, No. 1 Hospital Affiliated to Jilin University, Changchun, China.
- Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
- Department of Infectious Diseases, Xiangya Hospital, Central South University, Changsha, China.
- Department of Infectious Diseases, Henan Provincial People's Hospital, Zhengzhou, China.
Zitieren
APA
Liu, S., Wong, G. L., Fan, R., Niu, J., Ma, H., Liang, W., Lu, X., Xie, J., Shang, J., Xie, D., Liu, Y., Zhou, B., Xie, Q., Peng, J., Gao, H., Rao, H., Chen, J., Sheng, J., Shen, S., …, & Sun, J. (2025). Role of Early On-Treatment Serum HBV RNA Declines in Predicting Hepatocellular Carcinoma Risk in Patients With Chronic Hepatitis B. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2024.07.024
Vancouver
Liu S, Wong GL, Fan R, Niu J, Ma H, Liang W, et al. Role of Early On-Treatment Serum HBV RNA Declines in Predicting Hepatocellular Carcinoma Risk in Patients With Chronic Hepatitis B. Clinical Gastroenterology and Hepatology. 2025. doi:10.1016/j.cgh.2024.07.024
BibTeX
@article{Liu2025,
author = {Liu, Shi and Wong, Grace Lai-Hung and Fan, Rong and Niu, Junqi and Ma, Hong and Liang, Wanying and Lu, Xingyu and Xie, Jianping and Shang, Jia and Xie, Dongying and Liu, Yali and Zhou, Bin and Xie, Qing and Peng, Jie and Gao, Hongbo and Rao, Huiying and Chen, Jinjun and Sheng, Jifang and Shen, Sheng and Yang, Song and Dou, Xiaoguang and Zhang, Zhengang and Wong, Vincent Wai-Sun and Hou, Jinlin and Sun, Jian},
title = {Role of Early On-Treatment Serum HBV RNA Declines in Predicting Hepatocellular Carcinoma Risk in Patients With Chronic Hepatitis B},
journal = {Clinical Gastroenterology and Hepatology},
year = {2025},
doi = {10.1016/j.cgh.2024.07.024}
}
EUVIMED